清通方联合胰激肽原酶肠溶片对糖尿病肾病蛋白尿作用的临床观察

Clinical effects of Qintong prescription combined with pancreatic kininogenase enteric-coated tablets on proteinuria of diabetic nephropathy

目的观察清通方联合胰激肽原酶肠溶片对糖尿病肾病蛋白尿的作用。方法选取糖尿病肾病患者80例，将患者按治疗方法分为2组，每组40例患者分别用胰激肽原酶肠溶片（西药组）、胰激肽原酶肠溶片＋清通方（中西药联合组）治疗，比较治疗前后空腹血糖、糖化血红蛋白和尿微量白蛋白/肌酐的变化。结果与治疗前相比，2组治疗后空腹血糖、糖化血红蛋白和尿微量白蛋白/肌酐较治疗前明显降低（P〈0.01），其中治疗后中西药联合组尿微量白蛋白/肌酐与治疗后西药组尿微量白蛋白/肌酐相比，明显降低（P〈0.01）。结论清通方与胰激肽原酶肠溶片联用可明显降低糖尿病肾病患者蛋白尿水平，比西药单药治疗效果更好。

ObjectiveTo observe the clinical effects of Qintong prescription combined with pancreatic kininogenase enteric-coated tablets on proteinuria of diabetic nephropathy.MethodsRandomized parallel control study was carried out in the 2 groups, which were the western medicine group （or the pancreatic kininogenase enteric-coated tablet group） and the combined treatment group （or the combined Qintong prescription and pancreatic kininogenase enteric-coated tablet group）. Changes in the levels of fasting blood glucose （FBG）, HbA1C, urinary trace albumin/creatinine were observed and compared before and after treatment.ResultsAfter treatment, fasting glucose, glycosylated hemoglobin and the urine trace albumin/creatinine levels in the 2 groups were significantly decreased, as compared with those before treatment （P〈0.01）. After treatment, the levels of urine trace albumin/creatinine in the combined treatment group were significantly decreased, as compared with the western medicine group （P〈0.01）.ConclusionsQintong prescription combined with pancreatic kininogenase enteric-coated tablets could significantly reduce the level of proteinuria in the patients with diabetic nephropathy, which showed to have better therapeutic effect than that of the single western medicine therapy.